The Column Group, a science-driven venture capital firm, agreed to acquire the remaining 74% stake in NGM Bio, a pharmaceutical company, for $100m. "We conducted a thorough review of our financial and strategic alternatives, including remaining a publicly held company, with particular focus on NGM Bio’s ongoing need for significant additional funding. Based on this review, we believe that this negotiated transaction for Purchaser to acquire NGM Bio is in the best interest of the Unaffiliated Stockholders," Suzanne Sawochka Hooper, NGM Bio Chair.